SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of share certificate15-02-2023
15-02-2023
SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Statement On Deviation Or Variation In The Use Of Proceeds Of Preferential Issue
Statement on deviation or variation in the use of proceeds of Preferential Issue13-02-2023
SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. February 13, 2023
Outcome of the Board Meeting held today i.e. February 13, 202313-02-2023
SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Outcome Of The Board Meeting Held Today I.E. February 13, 2023
Outcome of the Board Meeting held today i.e. February 13, 202313-02-2023
SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Board Meeting Intimation for Considering And Approving The Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2022
SUN PHARMA ADVANCED RESEARCH COMPANY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2023 ,inter alia, to consider and approve the Unaudited Financial Results for the quarter and Nine Months ended December 31, 202204-02-2023
SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate by the holder27-01-2023
SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - "Launch Of SEZABY (Phenobarbital Sodium Powder For Injection) In The U.S. For The Treatment Of Neonatal Seizures".
We would like to inform that the Company has received an intimation from the partner about the launch of SEZABY (phenobarbital sodium powder for injection) in the U.S. for the treatment of neonatal seizures. The Company is eligible to receive US$ 5 million as milestone payment upon commercialization of SEZABY, the first and only product approved in U.S. for the treatment of neonatal seizures in term and preterm infants. Pursuant to the agreement between the parties, SPARC shall also be eligible for future milestones and royalties on net sales.25-01-2023
SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby furnish the details of request for issue of duplicate share certificate reported by shareholder of the Company20-01-2023
SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate by the holder20-01-2023
SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Submission Of Certificate From Statutory Auditor In Terms Of Regulation 169(5) Of The Securities And Exchange Board Of India (Issue Of Capital And Disclosure Requirements) Regulations, 2018
Submission of Certificate from Statutory Auditor in terms of Regulation 169(5) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 201818-01-2023